摘要
政府对企业的研发投入直接影响了企业的创新能力。针对新药研发投入高、风险大的医药行业,探讨我国政府R&D投入对医药制造企业R&D投入的影响,为政府和企业创新发展提供参考。通过构建医药制造企业R&D投入与政府R&D投入之间影响关系的回归模型,并采用2000—2015年样本数据进行实证分析,结果发现政府R&D投入对医药制造企业R&D投入具备诱导效应。因此,在"健康中国2030"战略规划下,政府应该加大R&D投入强度、优化R&D投入效率,医药制造企业也应当提高对R&D的重视意识,并有效利用R&D资金。
The government's research and development input in enterprises directly affects the innovation ability of enterprises. Aiming at the pharmaceutical industry with high investment and risk of R&D,this paper explores the impact of Chinese government R&D input on R&D investment in pharmaceutical manufacturing enterprises,and provides reference for government and enterprise innovation. By constructing a regression model of the relationship between R&D investment of pharmaceutical manufacturing enterprises and government R&D input in pharmaceutical manufacturing enterprises,and using the sample data from 2000 to 2015 for empirical analysis,it was found that government R&D input has an inductive effect on the R&D investment of pharmaceutical manufacturing enterprises. Therefore,under the"Healthy China 2030"strategic plan,the government should increase R&D input intensity and optimize the R&D input efficiency.Pharmaceutical manufacturing companies should also increase their awareness of R&D and make effective use of R&D funds.
引文
[1]DAVID P A,HALL B H,TOOLE A A.Is public R&D a complement or substitute for private R&D?A review of the econometric evidence[J].Research Policy,2000,29(4):497-529.
[2]ARQUé-CASTELLS P.Persistence in R&D performance and its implications for the granting of subsidies[J].Review of Industrial Organization,2013,43(3):193-220.
[3]GARZA D,GIAT Y,HACKMAN S T,et al.A computational analysis of R&D support programs[J].Economics of Innovation&New Technology,2015,24(7):1-28.
[4]王霞,顾琪虹,郭兵,等.政府R&D资助对企业R&D投入的作用---基于2008-2012年上海1480家民营企业数据的实证分析[J].技术经济,2014,33(4):1-7.
[5]CARMICHAEL J.The effects of mission-oriented public R&Dspending on private industry[J].Journal of Finance,1981,36(3):617-627.
[6]WALLSTEN S J.The effects of government-industry R&D programs on private R&D:The case of the small business innovation research program[J].Rand Journal of Economics,2000,31(1):82-100.
[7]张兴龙,沈坤荣,李萌.政府R&D投入是否促进了企业R&D经费支出---来自A股医药制造业上市公司的证据[J].产业经济研究,2014(5):53-62.
[8]王霞,吴小燕,郭兵,等.异质性视角下政府科技资助与企业R&D产出---基于上海市企业的实证研究[J].工业技术经济,2015(8):65-72.
[9]李平,王春晖.最优政府研发资助规模及资助企业选择---基于中国行业异质性的门槛回归分析[J].产业经济评论(山东),2010,9(3):37-53.
[10]杜文献,吴林海.政府R&D投入对企业R&D投入的诱导效应---基于1991-2004年中国科技统计数据的实证分析[J].科技进步与对策,2007,24(11):20-23.
[11]梁丹婴.基于面板数据的我国医药产业R&D绩效与科技引导政策关联性分析[J].科技管理研究,2011,31(15):36-40.
[12]刘凤朝,赵雪键,马荣康.政府采购促进了企业R&D投入吗?---基于中小企业上市公司的实证分析[J].科学学与科学技术管理,2017,38(7):42-52.
[13]Biotechnology Innovation Organization.Clinical development success rates 2006-2015[R].AMPLION,2016.
(1)2015年8月国务院关于改革药品医疗器械审评审批制度的意见(国发[2015]44号)对新药的概念进行了更改,由原来的“未曾在中国境内上市销售的药品”改为“未曾在中国境内外上市销售的药品”。